<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346914</url>
  </required_header>
  <id_info>
    <org_study_id>NTL-LEES-2019-03</org_study_id>
    <nct_id>NCT04346914</nct_id>
  </id_info>
  <brief_title>Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer</brief_title>
  <official_title>Phase Ib Study of Recombinant Anti-PD-L1 Monoclonal Antibody Injection (ZKAB001) Combined With Carboplatin and Etoposide in the Treatment of Extensive Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection&#xD;
      (ZKAB001) combined with carboplatin and etoposide in the treatment of extensive-stage small&#xD;
      cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and preliminary efficacy of recombinant anti-PD-L1（Programmed cell&#xD;
      death ligand 1）monoclonal antibody injection (ZKAB001) combined with carboplatin and&#xD;
      etoposide in the treatment of extensive-stage small cell lung cancer. The study will last&#xD;
      until the number of patients who permanently stop taking drugs due to toxicity in the first&#xD;
      two cycles is less than 1/3 of the total number of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>28 days after first dose</time_frame>
    <description>The number of patients who permanently stop taking drugs due to toxicity is less than 1/3 of the total number of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients in partial and complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>time between first dose of study drug to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The positive rate of PD-L1 expression in tumor tissue</measure>
    <time_frame>12 months</time_frame>
    <description>The positive rate of PD-L1 expression in tumor tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The positive rate of anti-drug antibody (ADA);</measure>
    <time_frame>12 months</time_frame>
    <description>The positive rate of anti-drug antibody (ADA);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>time between first dose of study drug to death caused by any reason</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Extensive Stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Combined treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide</intervention_name>
    <description>ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w</description>
    <arm_group_label>Combined treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  both men and women, age ≥ 18 years old and ≤ 75 years old.&#xD;
&#xD;
          -  histologically confirmed SCLC&#xD;
&#xD;
          -  extensive stage SCLC (ES-SCLC) according to (VALG) staging of American Veterans Lung&#xD;
             Cancer Association.&#xD;
&#xD;
          -  have not received first-line systemic therapy for ES-SCLC in the past.&#xD;
&#xD;
          -  surgery and adjuvant therapy for cure, such as radiotherapy and chemotherapy, were&#xD;
             performed in the past, and there was no treatment interval of at least 6 months from&#xD;
             the last chemotherapy, radiotherapy or radiotherapy or chemotherapy to the diagnosis&#xD;
             of ES-SCLC.&#xD;
&#xD;
          -  PS 0 or 1.&#xD;
&#xD;
          -  estimated survival time &gt; 12 weeks.&#xD;
&#xD;
          -  CT or MRI scan with at least one measurable lesion less than 28 days before the first&#xD;
             dose of the study drug (RECIST v1.1).&#xD;
&#xD;
          -  male subjects and women of childbearing age must have contraception within 6 months&#xD;
             from the beginning of the first drug study to the last study drug.&#xD;
&#xD;
          -  before the first dose of the drug, the laboratory test values met the following&#xD;
             conditions: (1) Blood routine test: WBC ≥ 3.0x10^9 / L, ANC ≥ 1.5x10^9 /L, PLT ≥&#xD;
             100x10^9 /L, hGB ≥ 90g / L; (2) liver function: AST ≤ 2.5 ULN, ALT ≤ 2.5 ULN; ALT and&#xD;
             AST &lt; 5 ULN for liver metastases; TBIL ≤ 1.5 ULN; ALB ≥ 30 g L; (3) Renal function:&#xD;
             serum creatinine ≤ 1.5 ULN or creatinine clearance rate (Ccr) ≥ 40 mL/min&#xD;
             (Cockcroft/Gault formula); (4) Coagulation function: INR ≤ 1.5, APTT ≤ 1.5 ULN; (5)&#xD;
             ALP ≤ 2.5 ULN, ALP ≤ 5 ULN. for bone metastasis subjects,&#xD;
&#xD;
          -  tumor tissue samples that can meet the detection of PD-L1 expression can be provided&#xD;
             during the screening period and within 4 weeks after selection.&#xD;
&#xD;
          -  voluntarily sign informed consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  before entering the group, the patients received any T cell co-stimulatory or immune&#xD;
             checkpoint inhibitors, including, but not limited to, cytotoxic T lymphocyte&#xD;
             associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors or other&#xD;
             drugs targeting T cells; previously received anti-vascular endothelial growth factor&#xD;
             (VEGF) or vascular endothelial growth factor receptor (VEGFR) therapy.&#xD;
&#xD;
          -  active brain metastasis or meningeal metastasis.&#xD;
&#xD;
          -  Patients with brain metastasis after treatment need to meet the following conditions:&#xD;
             asymptomatic; no imaging evidence of progress ≥ 4 weeks after treatment; completion of&#xD;
             treatment within 14 days before the first dose of the study drug; and no need to&#xD;
             receive systemic corticosteroids (&gt; 10mg/ prednisone or equivalent) less than 14 days&#xD;
             before the first dose of the study drug.&#xD;
&#xD;
          -  radiotherapy for the chest and whole brain was completed less than 4 weeks before the&#xD;
             first dose of the study drug (palliative radiotherapy for bone lesions is allowed ).&#xD;
&#xD;
          -  the third space effusion with clinical symptoms, such as pericardial effusion, pleural&#xD;
             effusion and peritoneal effusion which cannot be controlled by pumping or other&#xD;
             treatment.&#xD;
&#xD;
          -  active, known or suspected autoimmune diseases. Patients with vitiligo, type I&#xD;
             diabetes, residual hypothyroidism caused by autoimmune thyroiditis that only require&#xD;
             hormone replacement therapy, or are not expected to recur in the absence of external&#xD;
             stimulation can be included in the group.&#xD;
&#xD;
          -  corticosteroids (&gt; 10 mg/ prednisone or equivalent dose) or other immunosuppressants&#xD;
             were used within 14 days before the first study.&#xD;
&#xD;
        Inhalation or topical use of steroids and adrenal replacement steroids are allowed in the&#xD;
        absence of active autoimmune disease; for patients receiving short-term, systemic&#xD;
        immunosuppressive therapy, for example, glucocorticoids for nausea, vomiting, or allergic&#xD;
        reaction management or preventive use can be admitted after consultation with the sponsor.&#xD;
        Allow the use of salt corticosteroids in the treatment of postural hypotension and the use&#xD;
        of low-dose glucocorticoid supplements in the treatment of adrenocortical insufficiency;&#xD;
&#xD;
          -  subjects who had been vaccinated or planned to receive live vaccines within 4 weeks&#xD;
             before the first study.&#xD;
&#xD;
          -  Interstitial pneumonia (ILD) disease, drug-induced pneumonia, radiation pneumonia&#xD;
             requiring steroid treatment or active pneumonia with clinical symptoms.&#xD;
&#xD;
          -  active pulmonary tuberculosis or screening subjects with a history of active pulmonary&#xD;
             tuberculosis infection within 1 year before treatment, whether treated or not.&#xD;
&#xD;
          -  except for alopecia and fatigue, other toxicities caused by previous antineoplastic&#xD;
             therapy need to be restored to CTCAE 5.0 ≤ 1 before the first dose. Some other&#xD;
             toxicities caused by previous antineoplastic therapy are not expected to be resolved&#xD;
             and have long-term persistent sequelae, such as neurotoxicity caused by platinum-based&#xD;
             therapy, which are allowed to be included in the group.&#xD;
&#xD;
          -  uncontrolled hypertension (systolic blood pressure ≥ 140mmHg and / or diastolic blood&#xD;
             pressure ≥ 90 mmHg), history of hypertensive crisis or hypertensive encephalopathy.&#xD;
&#xD;
          -  there are uncontrolled clinical symptoms or diseases of the heart, such as: (1)heart&#xD;
             failure defined by New York Heart Association (NYHA)in grade 2 or above (2) unstable&#xD;
             angina pectoris (3) myocardial infarction within 6 months (4) clinically significant&#xD;
             supraventricular or ventricular arrhythmias need to be treated.&#xD;
&#xD;
          -  uncontrolled active infections (e.g. need intravenous antibiotics, antifungal or&#xD;
             antiviral therapy).&#xD;
&#xD;
          -  HIV infection, HBsAg positive and peripheral blood HBV-DNA titer ≥ 0.5 × 10^3 copies /&#xD;
             mL or HCV positive (HCV RNA or HCV Ab test indicated acute or chronic infection).&#xD;
&#xD;
          -  pregnant or lactating women.&#xD;
&#xD;
          -  known allergies to study drugs or excipients, and known severe allergic reactions to&#xD;
             any monoclonal antibody; allergic history of carboplatin or etoposide.&#xD;
&#xD;
          -  other malignant tumors occurred less than 5 years before the first dose, except for&#xD;
             fully treatable cervical carcinoma in situ, basal cell or squamous cell skin cancer,&#xD;
             local prostate cancer after radical resection, ductal carcinoma in situ after radical&#xD;
             resection, and breast cancer without recurrence and metastasis after radical&#xD;
             resection.&#xD;
&#xD;
          -  known cases of mental illness, alcohol abuse, inability to quit smoking, drug use or&#xD;
             substance abuse.&#xD;
&#xD;
          -  have been treated with any other experimental drugs or participated in another&#xD;
             interventional clinical study within 4 weeks before signing ICF&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Lu, doctor</last_name>
      <phone>+8621-62821990</phone>
      <email>shun_lu@hotmail.com</email>
    </contact>
    <contact_backup>
      <phone>＋8618017321552</phone>
      <email>drchenzhiwei@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ES-SCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

